Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555399 · ClinicalTrials.gov registry record · Phase 1
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00555399: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00555399 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00555399, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if vorinostat when given with isotretinoin and temozolomide can help to control glioblastoma or gliosarcoma. The safety of these drug combinations will also be studied.
Interventions
- PROCEDURE Surgical Resection
- DRUG Temozolomide
- DRUG Vorinostat
- DRUG Isotretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-11-28 |
| Est. Completion | 2020-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00555399
The ClinicalTrials.gov registry entry for NCT00555399 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Surgical Resection is the first listed.
NCT00555399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00555399 about?
NCT00555399 is a clinical study titled "Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)". The goal of this clinical research study is to learn if vorinostat when given with isotretinoin and temozolomide can help to control glioblastoma or gliosarcoma. The safety of these drug combinations will also be studied.
What is the current status of trial NCT00555399?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2007-11-28. Estimated completion is 2020-01-24.
What interventions are being tested in trial NCT00555399?
The interventions under investigation include: Surgical Resection (PROCEDURE), Temozolomide (DRUG), Vorinostat (DRUG), Isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00555399?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.